治療攝護腺肥大藥物之探討

The Pathology and Treatment of Benign Prostate Hyperplasia: Current concepts

10.6202/THJ.201712_(13).0006

高久理(Chiu-Li Kao)；曾于庭(Yu-Ting Tseng)；林維楨(Wei-Chen Lin)；劉棋銘(Chi-Ming Liu)

攝護腺肥大 ； α-腎上腺受體拮抗劑 ； 5α-還原酶抑製劑 ； benign prostate hyperplasia ； α-adrenergic antagonist ； 5α-reductase inhibitor

慈惠學報

13期（2017 / 12 / 01）

78 - 88

繁體中文

攝護腺肥大普遍發生於老年族群。攝護腺肥大使病患產生下泌尿道症候群。年齡、荷爾蒙、生長因子、發炎和生活方式會影響攝護腺肥大的發展。臨床上α-腎上腺受體拮抗劑和5α-還原酶抑製劑用於治療攝護腺肥大之症狀與排尿障礙。在本文中，我們將進一步探討藥物於治療攝護腺肥大之分子藥理機制與攝護腺肥大治療新趨勢。

Benign prostate hyperplasia (BPH) is highly prevalent in the aging population, particularly in men. Prostate enlargement leads to male lower urinary tract symptoms (LUTS). Several factors cause the development of benign prostate hyperplasia including age, hormones, growth factors, inflammation, and lifestyle. In clinical setting, α -adrenergic antagonists and 5α-reductase inhibitors are used for the treatment of BPH. In this article, we will discuss the molecule mechanisms of action of drug and new concepts in the treatment of BPH.

1. Batty, M.,Pugh, R.,Rathinam, I.,Simmonds, J.,Walker, E.,Forbes, A.,Chess‐Williams, R.(2016).The Role of alpha1‐Adrenoceptor Antagonists inthe Treatment of Prostate and Other Cancers.Int J Mol Sci,17(8)
2. Benning, C. M.,Kyprianou, N.(2002).Quinazoline‐derived alpha1‐adrenoceptorantagonists induce prostate cancer cell apoptosis via analpha1‐adrenoceptor‐independent action.Cancer Res,62(2),597-602.
3. Burnett, A. L.,Wein, A. J.(2006).Benign prostatic hyperplasia in primary care: whatyou need to know.J Urol,175(3 Pt 2),S19-S24.
4. Cal, C.,Uslu, R.,Gunaydin, G.,Ozyurt, C.,Omay, S. B.(2000).Doxazosin: a newcytotoxic agent for prostate cancer?.BJU Int,85(6),672-675.
5. Calmasini, F. B.,Silva, F. H.,Alexandre, E. C.,Rodrigues, R. L.,Barbosa, A. P.,Ferrucci,D. L.,Antunes, E.(2017).Implication of Rho‐kinase and soluble guanylylcyclase enzymes in prostate smooth muscle dysfunction in middle‐aged rats.Neurourol Urodyn,36(3),589-596.
6. Chughtai, B.,Thomas, D.,Kaplan, S.(2016).alpha‐Blockers, 5‐alpha‐ReductaseInhibitors, Acetylcholine, beta3 Agonists, and Phosphodiesterase‐5s inMedical Management of Lower Urinary Tract Symptoms/Benign ProstaticHyperplasia: How Much Do the Different Formulations Actually Matter in the Classes?.Urol Clin North Am,43(3),351-356.
7. Dimitropoulos, K.,Gravas, S.(2015).Solifenacin/tamsulosin fixed‐dosecombination therapy to treat lower urinary tract symptoms in patients withbenign prostatic hyperplasia.Drug Des Devel Ther,9,1707-1716.
8. Fulton, B.,Wagstaff, A. J.,Sorkin, E. M.(1995).Doxazosin. An update of its clinicalpharmacology and therapeutic applications in hypertension and benignprostatic hyperplasia.Drugs,49(2),295-320.
9. Garrison, J. B.,Kyprianou, N.(2006).Doxazosin induces apoptosis of benign andmalignant prostate cells via a death receptor‐mediated pathway.Cancer Res,66(1),464-472.
10. Hernandez, C.,Morote, J.,Minana, B.,Cozar, J. M.(2013).The role ofprostate‐specific antigen in light of new scientific evidence.Actas Urol Esp,37(6),324-329.
11. Kyprianou, N.,Benning, C. M.(2000).Suppression of human prostate cancer cell growth by alpha1‐adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.Cancer Res,60(16),4550-4555.
12. Kyprianou, N.,Chon, J.,Benning, C. M.(2000).Effects of alpha(1)‐adrenoceptor(alpha(1)‐AR) antagonists on cell proliferation and apoptosis in the prostate:therapeutic implications in prostatic disease.Prostate Suppl,9,42-46.
13. Lee, C. L.,Kuo, H. C.(2017).Pathophysiology of benign prostate enlargement andlower urinary tract symptoms: Current concepts.Ci Ji Yi Xue Za Zhi,29(2),79-83.
14. Lepor, H.(2016).Alpha‐blockers for the Treatment of Benign Prostatic Hyperplasia.Urol Clin North Am,43(3),311-323.
15. Liao, C. H.,Kuo, H. C.(2017).Current consensus and controversy on the treatmentof male lower urinary tract symptoms/benign prostatic hyperplasia.Ci Ji YiXue Za Zhi,29(1),1-5.
16. Lin, S. C.,Chueh, S. C.,Hsiao, C. J.,Li, T. K.,Chen, T. H.,Liao, C. H.,Guh, J. H.(2007).Prazosin displays anticancer activity against human prostate cancers:targeting DNA and cell cycle.Neoplasia,9(10),830-839.
17. Liu, L.,Zhao, S.,Li, F.,Li, E.,Kang, R.,Luo, L.,Zhao, Z.(2016).Effect of5alpha‐Reductase Inhibitors on Sexual Function: A Meta‐Analysis andSystematic Review of Randomized Controlled Trials.J Sex Med,13(9),1297-1310.
18. Liu, L.,Zheng, S.,Han, P.,Wei, Q.(2011).Phosphodiesterase‐5 inhibitors for lowerurinary tract symptoms secondary to benign prostatic hyperplasia: asystematic review and meta‐analysis.Urology,77(1),123-129.
19. Minciullo, P. L.,Inferrera, A.,Navarra, M.,Calapai, G.,Magno, C.,Gangemi, S.(2015).Oxidative stress in benign prostatic hyperplasia: a systematic review.Urol Int,94(3),249-254.
20. Moss, M. C.,Rezan, T.,Karaman, U. R.,Gomelsky, A.(2017).Treatment ofConcomitant OAB and BPH.Curr Urol Rep,18(1),1.
21. Peixoto, C. A.,Gomes, F. O.(2015).The role of phosphodiesterase‐5 inhibitors inprostatic inflammation: a review.J Inflamm (Lond),12,54.
22. Presicce, F.,De Nunzio, C,Tubaro, A.(2017).Can Long‐term LUTS/BPHPharmacological Treatment Alter the Outcomes of Surgical Intervention?.CurrUrol Rep,18(9),72.
23. Russo, A.,Capogrosso, P.,La Croce, G.,Ventimiglia, E.,Boeri, L.,Briganti, A.,Salonia, A.(2016).Serenoa repens, selenium and lycopene to manage lowerurinary tract symptoms suggestive for benign prostatic hyperplasia.Expert Opin Drug Saf,15(12),1661-1670.
24. Saito, M.,Ohmasa, F.,Shomori, K.,Dimitriadis, F.,Ohiwa, H.,Shimizu, S.,Satoh, K.(2011).Rhos and Rho kinases in the rat prostate: their possible functionalroles and distributions.Mol Cell Biochem,358(1?2),207-213.
25. Speakman, M. J.(2009).PDE5 inhibitors in the treatment of LUTS.Curr Pharm Des,15(30),3502-3505.
26. Udensi, U. K.,Tchounwou, P. B.(2016).Oxidative stress in prostate hyperplasia andcarcinogenesis.J Exp Clin Cancer Res,35(1),139.
27. Wang, X.,Wang, X.,Li, S.,Meng, Z.,Liu, T.,Zhang, X.(2014).Comparativeeffectiveness of oral drug therapies for lower urinary tract symptoms due tobenign prostatic hyperplasia: a systematic review and network meta‐analysis.PLoS One,9(9),e107593.
28. Wilt, T. J.,MacDonald, R.(2006).Doxazosin in the treatment of benign prostatichypertrophy: an update.Clin Interv Aging,1(4),389-401.
29. Wong, P.,Lawrentschuk, N.,Bolton, D. M.(2009).Phosphodiesterase 5 inhibitors inthe management of benign prostatic hyperplasia and erectile dysfunction: thebest of both worlds.Curr Opin Urol,19(1),7-12.
30. Yan, H.,Zong, H.,Cui, Y.,Li, N.,Zhang, Y.(2014).The efficacy of PDE5 inhibitorsalone or in combination with alpha‐blockers for the treatment of erectiledysfunction and lower urinary tract symptoms due to benign prostatichyperplasia: a systematic review and meta‐analysis.J Sex Med,11(6),1539-1545.
31. Zhao, H.,Lai, F.,Nonn, L.,Brooks, J. D.,Peehl, D. M.(2005).Molecular targets ofdoxazosin in human prostatic stromal cells.Prostate,62(4),400-410.